NCT07538570 Evaluation of Pain Treatment After Total Knee Arthroplasty
| NCT ID | NCT07538570 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Condition | Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-04-24 |
| Primary Completion | 2027-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 60 participants in total. It began in 2026-04-24 with a primary completion date of 2027-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Eligibility Criteria
Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07538570 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07538570 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07538570 currently recruiting?
Yes, NCT07538570 is actively recruiting participants. Contact the research team at medicalinfo@vrtx.com for enrollment information.
Where is the NCT07538570 trial being conducted?
This trial is being conducted at Bellaire, United States, Houston, United States.
Who is sponsoring the NCT07538570 clinical trial?
NCT07538570 is sponsored by Vertex Pharmaceuticals Incorporated. The trial plans to enroll 60 participants.